Keyphrases
Checkpoint Inhibitors
100%
Murine Melanoma
100%
Oncolytic Newcastle Disease Virus
100%
Radiotherapy
71%
Newcastle Disease Virus
71%
Anti-CTLA-4
71%
Monoclonal Antibody
28%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
28%
Oncolytic Virus
28%
Complete Tumor Regression
28%
Adverse Effects
14%
National Institutes of Health
14%
Tumor
14%
Melanoma
14%
T Cells
14%
Clinical Outcomes
14%
Systemic Administration
14%
Murine Model
14%
Overall Survival
14%
Chemotherapy
14%
Antibody Targeting
14%
Antitumor Effect
14%
Negative Regulator
14%
Transgenic
14%
Improved Efficacy
14%
Immunogenic Tumor
14%
Tumor Size
14%
Clinical Efficacy
14%
Response Rate
14%
Survival Benefit
14%
Programmed Death-ligand 1 (PD-L1)
14%
Immunotherapeutics
14%
Reduced Toxicity
14%
Antitumor Efficacy
14%
Clinical Testing
14%
ScFv
14%
Single-chain Variable Fragment
14%
Systemic Exposure
14%
Radiotherapy Dose
14%
Design Information
14%
Anti-PD-1
14%
Single Therapy
14%
Intratumor
14%
Abscopal Effect
14%
Neoplastic Disease
14%
B16F10
14%
Recombinant Newcastle Disease Virus
14%
Murine Melanoma Model
14%
CTLA-4 Inhibitors
14%
Checkpoint Molecules
14%
Dose Sparing
14%
Tumor Clearance
14%
In Vivo Expression
14%
Cold Tumor
14%
Analysis Decision
14%
Tumor Regression Rate
14%
Decision to Publish
14%
ScFv Antibody
14%
Checkpoint Inhibitor Blockade
14%
Medicine and Dentistry
Melanoma
100%
Newcastle Disease Virus
100%
Tumor
75%
Radiation Therapy
75%
Monoclonal Antibody
37%
Tumor Regression
25%
Oncolytic Virus
25%
Single Chain Fragment Variable Antibody
25%
Neoplasm
12%
Immunotherapy
12%
Overall Survival
12%
T Cell
12%
Combined Therapy
12%
Immunomodulating Agent
12%
Intratumoral Drug Administration
12%
Programmed Death-Ligand 1
12%
Systemic Administration
12%
Abscopal Effect
12%
Adverse Effect
12%
Pharmacology, Toxicology and Pharmaceutical Science
Newcastle Disease Virus
100%
Melanoma
100%
Cytotoxic T Lymphocyte Antigen 4
100%
Monoclonal Antibody
37%
Tumor Regression
25%
Murine
25%
Single Chain Fragment Variable Antibody
25%
Oncolytic Virus
25%
Neoplasm
12%
Immunotherapy
12%
Overall Survival
12%
Chemotherapy
12%
Immunomodulating Agent
12%
Systemic Administration
12%
Immunology and Microbiology
Newcastle Disease Virus
100%
Monoclonal Antibody
37%
Murine
25%
Single-Chain Variable Fragment
25%
Oncolytic Virus
25%
Immunotherapy
12%
T Cell
12%
Overall Survival
12%
Tumor Volume
12%
Immunomodulating Drugs
12%
Transgenics
12%
Programmed Death-Ligand 1
12%
Biochemistry, Genetics and Molecular Biology
Newcastle Disease Virus
100%
Monoclonal Antibody
37%
Murine
25%
Single-Chain Variable Fragment
25%
T Cell
12%
Transgenics
12%
Overall Survival
12%
Tumor Volume
12%
PD-L1
12%